Metrics as of 10/17/2026, 08:52 AM (Berlin time), refresh in progress.
Immunocore Holdings Stock
Immunocore Holdings plc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Bahija Jallal
- Employees
- 524
- Market cap
- $1.5 B
- IPO
- 05/02/2021
Immunocore Holdings plc is a biotechnology firm established in 1999 and based in Abingdon, United Kingdom. The company has reached the commercial stage in its mission to create pioneering immunotherapies. Its development pipeline addresses a range of serious conditions, including various cancers, infectious diseases,…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Immunocore Holdings stock: price history
1D
-0.3%
1W
+0.0%
1M
-6.9%
6M
-6.5%
YTD
-15.3%
1Y
-12.3%
2Y
-11.6%
5Y
-22.6%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~7% stronger price swings than usual
Ask the agents about Immunocore Holdings
Analyst assessment of Immunocore Holdings
PRICE TARGET LOW
US$35.00
CONSENSUS
US$39.00
MEDIAN
US$39.00
PRICE TARGET HIGH
US$43.00
0
STRONG BUY
9
BUY
5
HOLD
0
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 03/08/2026
Immunocore Holdings stock metrics
P/E
-163.06
P/B
3.57
EV/EBITDA
85.82
RETURN ON EQUITY
-0.2%
NET MARGIN
-0.7%
DEBT/EQUITY
1.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
92.3%
FLOAT SHARES
45,834,799
AVG. DAILY VOLUME (30D)
444,789
Institutional holders
Comparable stocks
Frequently asked questions about Immunocore Holdings stock
What does Immunocore Holdings do?
Immunocore Holdings plc is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Bahija Jallal, the company employs around 524 people.
The IPO was on 05/02/2021; the stock trades on NASDAQ under the ticker IMCR.
What do analysts say about Immunocore Holdings stock?
14 analysts rate the stock, the consensus is Buy (as of 03/08/2026).
The average price target is US$39.00, ranging from US$35.00 to US$43.00, with a median of US$39.00.
This is an external assessment, not a statement by Market Jury.
When does Immunocore Holdings report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 7% stronger than usual.
Does Immunocore Holdings pay a dividend?
No, Immunocore Holdings currently does not pay a dividend.
Which stocks are comparable to Immunocore Holdings?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Immunocore Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Immunocore Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.